Aviance Capital Management’s GSK GSK Stock Holding History

Aviance Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$4.65M	Sell	89,080 -94,050	-51%	-$4.7M	0.7%	45
2018 Q4	$8.75M	Buy	183,130 +52,951	+41%	+$2.61M	1.23%	24
2018 Q3	$6.54M	Buy	130,179 +123,610	+1,882%	+$6.28M	0.64%	43
2018 Q2	$331K	Sell	6,569 -502	-7%	-$25.3K	0.03%	141
2018 Q1	$345K	Buy	7,071 +89	+1%	+$4.14K	0.03%	168
2017 Q4	$310K	Sell	6,982 -82,708	-92%	-$3.82M	0.02%	162
2017 Q3	$4.55M	Sell	89,690 -10,172	-10%	-$516K	0.31%	58
2017 Q2	$5.38M	Sell	99,862 -14,854	-13%	-$792K	0.34%	62
2017 Q1	$6.05M	Sell	114,716 -10,742	-9%	-$545K	0.34%	63
2016 Q4	$6.04M	Sell	125,458 -558,254	-82%	-$27.6M	0.32%	66
2016 Q3	$36.9M	Sell	683,712 -18,074	-3%	-$991K	1.02%	25
2016 Q2	$38M	Buy	701,786 +282,198	+67%	+$14.9M	1.14%	23
2016 Q1	$21.3M	Buy	419,588 +97,954	+30%	+$4.88M	0.7%	41
2015 Q4	$16.2M	Buy	321,634 +59,371	+23%	+$3.03M	0.53%	53
2015 Q3	$12.6M	Buy	+262,263	New	+$13.7M	0.44%	59
2015 Q2	–	Sell	-186,692	Closed	-$10.8M	–	123
2015 Q1	$10.8M	Sell	186,692 -204,142	-52%	-$11.7M	0.4%	54
2014 Q4	$20.9M	Sell	390,834 -55,968	-13%	-$3.13M	0.75%	43
2014 Q3	$25.7M	Buy	446,802 +83,061	+23%	+$5.09M	1.03%	28
2014 Q2	$24.3M	Buy	363,741 +128,771	+55%	+$8.72M	1.03%	24
2014 Q1	$15.7M	Buy	234,970 +229,452	+4,158%	+$15.5M	0.8%	34
2013 Q4	$368K	Buy	5,518 +267	+5%	+$17.3K	0.2%	89
2013 Q3	$329K	Sell	5,251 -22,442	-81%	-$1.44M	0.19%	98
2013 Q2	$1.73M	Buy	+27,693	New	+$1.76M	0.95%	35

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Aviance Capital Management's GSK Position: Q1 2019 in Review

Aviance Capital Management reduced its GSK (GSK) stake by 51% in Q1 2019, selling an estimated $4.7M and leaving 89,080 shares worth $4.65M. The position accounts for 0.7% of the portfolio, ranked #45.

Aviance Capital Management first reported a position in GSK in Q2 2013 and has held it in 23 quarters since. The position peaked at $38M in Q2 2016. 848 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

Aviance Capital Management held 89,080 shares of GSK worth $4.65M as of Q1 2019.
Aviance Capital Management sold 94,050 GSK shares in Q1 2019, an estimated $4.7M.
GSK made up 0.7% of Aviance Capital Management's portfolio in Q1 2019, its #45 holding.
Aviance Capital Management first reported a position in GSK in Q2 2013 and has held it in 23 quarters since.
Aviance Capital Management's GSK position peaked at $38M in Q2 2016.
848 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on Aviance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.